- Home
- VCNX
VCNX
Vaccinex Inc.
as 11-15-2024 4:00pm EST
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | ROCHESTER |
| Market Cap: | 4.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 167.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.39 - $13.02 | Next Earning Date: | 11-29-2024 |
| Revenue: | $388,000 | Revenue Growth: | -56.85% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Vaccinex Inc. News
VCNX Breaking Stock News: Dive into VCNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
GlobeNewswire
13 days ago
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
GlobeNewswire
18 days ago
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
GlobeNewswire
25 days ago
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
MT Newswires
2 months ago
Top Midday Decliners
GlobeNewswire
2 months ago
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
GlobeNewswire
3 months ago
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
Clinical Trials Arena
4 months ago
Vaccinex’s Phase Ib/II trial for Alzheimer’s treatment hits primary endpoint
Compare VCNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VCNX Vaccinex Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.